Resources

Resource centre

Navigating the Small Molecule CMC Pathway

Learn about drug substance and formulation considerations for improving downstream clinical outcomes. Access on demand.

Streamlining the Delivery of 14C Human ADME Data: An ADME Q&A Roundtable

Experts from Quotient Sciences and The Netherlands Organization for Applied Scientific Research (TNO) discuss streamlining human ADME studies.

Non-Clinical vs Clinical: Risks & Considerations When Developing Modified Release Dosage Forms

Dr. Vanessa Zann, Senior Drug Development Consultant, discusses specialized technologies used to optimize modified-release formulations.

Getting it Right Early: The Importance of Biopharmaceutics in Early Drug Development

Chris Roe, Quotient Sciences' Principal Research Fellow, discusses strategies for overcoming biopharmaceutic challenges for small molecules in today’s drug development.

Moving Drug Substance Off the Critical Path: Streamlined Strategies to Accelerate to First-in-Human & Beyond

Watch our on demand webinar to hear Dr. Stephen McQuaker, Director of Drug Development Consulting, as he explores case studies to demonstrate how drug substance and drug product development plans can be accelerated through innovative science and expertise to get drug substance off the critical path.

Overcoming Complex Formulation Challenges: Integrated Strategies for Poor Solubility, Modified Release & Pediatrics

Watch our on-demand webinar featuring John McDermott, VP of Scientific Consulting at Quotient Sciences, who discusses how an integrated program design can simplify development processes for complex molecules and reduce overall costs.

Tufts CSDD Study Assessing the Financial Benefits of Translational Pharmaceutics®: A Platform for Accelerating Product Development

This webinar summarizes the key findings of the recent Tufts CSDD research into Translational Pharmaceutics, the innovative approach to drug development. Access our on-demand webinar now.

First-in-Human to Proof-Of-Concept: Addressing Development Challenges and Accelerating Timelines

Increasing pressure on R&D budgets means the design, speed and precision of early phase clinical programs is critical for success.